Probi and Perrigo have signed an “extensive” pan-European agreement enabling the companies to expand probiotic digestive and immune health concepts into 14 European countries, according to a press release. Financial terms were not disclosed.
Under the agreement, Perrigo will launch three probiotic products as dietary supplements within the digestive and immune areas based on Probi’s clinically studied strains. The first launch is planned to take place in 2021.
Svend Andersen, EVP and President of Consumer Self-Care International at Perrigo, said in the press release: “It is very important for Perrigo to enter the probiotic space together with a renowned probiotic innovator with a strong emphasis on scientifically validated probiotic concepts. This partnership will strengthen our self-care portfolio and enable Perrigo to gain a solid foothold within probiotics in many European countries. We are delighted to take this step together with Probi.”
“We see the collaboration between Probi and Perrigo as an important step in our commercial efforts in offering clinically documented probiotic products to European consumers in partnership with successful consumer healthcare companies,” added Tom Rönnlund, CEO at Probi. “We are excited to enter a partnership with Perrigo, where we feel full alignment and confidence on important parameters like research, quality, and performance. I strongly believe that this will strengthen the Probi brand on a global scale.”